Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
1.13
USD
|
+4.63%
|
|
+0.89%
|
+30.23%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
30.84
|
8.148
|
30.16
|
42.5
|
-
|
-
|
Enterprise Value (EV)
1 |
30.84
|
8.148
|
30.16
|
42.5
|
42.5
|
42.5
|
P/E ratio
|
-2.4
x
|
-0.45
x
|
-0.68
x
|
-2.05
x
|
-3.59
x
|
0.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
32.7%
|
Capitalization / Revenue
|
-
|
8.57
x
|
44.7
x
|
-
|
1.74
x
|
0.17
x
|
EV / Revenue
|
-
|
8.57
x
|
44.7
x
|
-
|
1.74
x
|
0.17
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-5.32
x
|
-
|
-
|
-0.82
x
|
-1.01
x
|
0.63
x
|
FCF Yield
|
-18.8%
|
-
|
-
|
-122%
|
-98.8%
|
158%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,973
|
15,089
|
34,754
|
37,606
|
-
|
-
|
Reference price
2 |
2.060
|
0.5400
|
0.8677
|
1.130
|
1.130
|
1.130
|
Announcement Date
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.951
|
0.675
|
-
|
24.39
|
248.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-8.977
|
-18.05
|
-20.77
|
-26.07
|
-29.23
|
131
|
Operating Margin
|
-
|
-
|
-1,898.21%
|
-3,077.63%
|
-
|
-119.83%
|
52.78%
|
Earnings before Tax (EBT)
1 |
-
|
-10.02
|
-18.06
|
-30.54
|
-25.81
|
-28.29
|
147.9
|
Net income
1 |
-2.264
|
-10.02
|
-18.06
|
-31.41
|
-25.81
|
-28.29
|
103.9
|
Net margin
|
-
|
-
|
-1,898.84%
|
-4,653.48%
|
-
|
-115.98%
|
41.87%
|
EPS
2 |
-0.2580
|
-0.8600
|
-1.200
|
-1.280
|
-0.5525
|
-0.3150
|
1.640
|
Free Cash Flow
1 |
-
|
-5.796
|
-
|
-
|
-52
|
-42
|
67
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-172.19%
|
26.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
64.46%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
0.3700
|
Announcement Date
|
2/18/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.951
|
-
|
0.675
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.715
|
-2.752
|
-3.537
|
-3.636
|
-5.554
|
-5.325
|
-4.202
|
-4.322
|
-5.938
|
-6.313
|
-6.258
|
-6.455
|
-6.542
|
-6.819
|
-6.408
|
Operating Margin
|
-
|
-
|
-
|
-
|
-584.02%
|
-
|
-622.52%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-5.201
|
-2.752
|
-3.537
|
-3.636
|
-5.557
|
-5.328
|
-14.58
|
-3.838
|
-4.333
|
-7.798
|
-6.277
|
-6.484
|
-6.387
|
-6.665
|
-6.408
|
Net income
1 |
-5.201
|
-2.752
|
-3.537
|
-3.636
|
-5.557
|
-5.328
|
-14.77
|
-4.441
|
-4.405
|
-8.665
|
-6.277
|
-6.484
|
-6.387
|
-6.665
|
-6.408
|
Net margin
|
-
|
-
|
-
|
-
|
-584.33%
|
-
|
-2,187.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3700
|
-0.1700
|
-0.2400
|
-0.2400
|
-0.3700
|
-0.3500
|
-0.9700
|
-0.2900
|
-0.1300
|
-0.1600
|
-0.1550
|
-0.1325
|
-0.1175
|
-0.1075
|
-0.1000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/31/22
|
5/12/22
|
8/15/22
|
11/14/22
|
3/31/23
|
5/16/23
|
8/14/23
|
11/14/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-5.8
|
-
|
-
|
-52
|
-42
|
67
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0
|
-
|
16
|
8
|
2
|
Capex / Sales
|
-
|
-
|
0.21%
|
-
|
-
|
32.8%
|
0.81%
|
Announcement Date
|
2/18/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.13
USD Average target price
5.3
USD Spread / Average Target +369.03% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.23% | 42.5M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|